119 related articles for article (PubMed ID: 36242915)
1. Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression.
Lapierre JA; Geary LA; Jang JK; Epstein AL; Hong F; Shih JC
Biochem Biophys Res Commun; 2022 Dec; 634():100-107. PubMed ID: 36242915
[TBL] [Abstract][Full Text] [Related]
2. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.
Liao CP; Lin TP; Li PC; Geary LA; Chen K; Vaikari VP; Wu JB; Lin CH; Gross ME; Shih JC
Oncogene; 2018 Sep; 37(38):5175-5190. PubMed ID: 29844571
[TBL] [Abstract][Full Text] [Related]
3. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression.
Garcia AJ; Ruscetti M; Arenzana TL; Tran LM; Bianci-Frias D; Sybert E; Priceman SJ; Wu L; Nelson PS; Smale ST; Wu H
Mol Cell Biol; 2014 Jun; 34(11):2017-28. PubMed ID: 24662052
[TBL] [Abstract][Full Text] [Related]
4. Targeting monoamine oxidase A for T cell-based cancer immunotherapy.
Wang X; Li B; Kim YJ; Wang YC; Li Z; Yu J; Zeng S; Ma X; Choi IY; Di Biase S; Smith DJ; Zhou Y; Li YR; Ma F; Huang J; Clarke N; To A; Gong L; Pham AT; Moon H; Pellegrini M; Yang L
Sci Immunol; 2021 May; 6(59):. PubMed ID: 33990379
[TBL] [Abstract][Full Text] [Related]
5. Targeting monoamine oxidase A-regulated tumor-associated macrophage polarization for cancer immunotherapy.
Wang YC; Wang X; Yu J; Ma F; Li Z; Zhou Y; Zeng S; Ma X; Li YR; Neal A; Huang J; To A; Clarke N; Memarzadeh S; Pellegrini M; Yang L
Nat Commun; 2021 Jun; 12(1):3530. PubMed ID: 34112755
[TBL] [Abstract][Full Text] [Related]
6. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-1α inhibition augments efficacy of programmed cell death 1 antibody in murine prostatic cancer models.
Shen Z; Pei Q; Zhang H; Yang C; Cui H; Li B; Liu J; Bo Z; Wei F; Zhang M; Liu C
Anticancer Drugs; 2022 Jul; 33(6):587-594. PubMed ID: 35324523
[TBL] [Abstract][Full Text] [Related]
8. Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy.
Shih JC
J Neural Transm (Vienna); 2018 Nov; 125(11):1553-1566. PubMed ID: 30259128
[TBL] [Abstract][Full Text] [Related]
9. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
10. Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment.
Qi Z; Xu Z; Zhang L; Zou Y; Li J; Yan W; Li C; Liu N; Wu H
Nat Commun; 2022 Jan; 13(1):182. PubMed ID: 35013322
[TBL] [Abstract][Full Text] [Related]
11. Monoamine oxidase A (MAOA): A promising target for prostate cancer therapy.
Han H; Li H; Ma Y; Zhao Z; An Q; Zhao J; Shi C
Cancer Lett; 2023 Jun; 563():216188. PubMed ID: 37076041
[TBL] [Abstract][Full Text] [Related]
12. PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma.
Li PC; Chen SY; Xiangfei D; Mao C; Wu CH; Shih JC
BMC Complement Med Ther; 2020 Aug; 20(1):252. PubMed ID: 32799864
[TBL] [Abstract][Full Text] [Related]
13. Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
van Duijn PW; Marques RB; Ziel-van der Made ACJ; van Zoggel HJAA; Aghai A; Berrevoets C; Debets R; Jenster G; Trapman J; van Weerden WM
Prostate; 2018 Sep; 78(13):1013-1023. PubMed ID: 30133757
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.
Sturgill ER; Rolig AS; Linch SN; Mick C; Kasiewicz MJ; Sun Z; Traber PG; Shlevin H; Redmond WL
Oncoimmunology; 2021 Mar; 10(1):1892265. PubMed ID: 33717655
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models.
Lin YX; Wang Y; Ding J; Jiang A; Wang J; Yu M; Blake S; Liu S; Bieberich CJ; Farokhzad OC; Mei L; Wang H; Shi J
Sci Transl Med; 2021 Jun; 13(599):. PubMed ID: 34162754
[TBL] [Abstract][Full Text] [Related]
17. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
18. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
19. High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors.
Lin L; Kane N; Kobayashi N; Kono EA; Yamashiro JM; Nickols NG; Reiter RE
Clin Cancer Res; 2021 Mar; 27(5):1505-1515. PubMed ID: 33219015
[TBL] [Abstract][Full Text] [Related]
20. The Antiproliferative Effects of Flavonoid MAO Inhibitors on Prostate Cancer Cells.
Zarmouh NO; Messeha SS; Mateeva N; Gangapuram M; Flowers K; Eyunni SVK; Zhang W; Redda KK; Soliman KFA
Molecules; 2020 May; 25(9):. PubMed ID: 32403270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
